piclozotan
Small moleculeexperimental
Piclozotan (SUN-N4057) is a selective 5-HT1A receptor partial agonist, which has neuroprotective effects in animal studies. It has been through early clinical trials in humans for treatment of acute stroke, but results have not yet been announced. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00272909)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
HTR1A agonist
Not in current pipelines.
Chemistry & pharmacology
Loading structure…
SMILES
O=C1c2ccccc2OC=C(Cl)N1CCCCN1CC=C(c2ccccn2)CC1- Mol. weight
- 409.92 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPiclozotan ↗
- ChEMBLCHEMBL345237 ↗
Also known as
- piclozota
- piclozotan
- piclozotan
- piclozotan
- piclozotan
- sun-n4057
- sun-n4057
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00623363 | Phase 2 | Apr 1, 2007 | Daiichi Sankyo |
| NCT00272909 | Phase 2 | Sep 1, 2004 | Daiichi Sankyo |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 2 | 2 | 1 | 2004 |
1 organizations
Page 1 / 1